{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T04:27:13Z","timestamp":1770956833341,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ejps.2019.105173","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T02:18:14Z","timestamp":1575339494000},"page":"105173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Repurposing of Iloperidone: Antihypertensive and ocular hypotensive activity in animals"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9889-0571","authenticated-orcid":false,"given":"Shrikant V.","family":"Joshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekta P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavin A.","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandesh R.","family":"Lodha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gajanan G.","family":"Kalyankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejps.2019.105173_bib0001","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.ejps.2019.105173_bib0002","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1076\/ceyr.23.2.144.5480","article-title":"Flesinoxan, a 5-HT1A receptor agonist\/alpha 1-adrenoceptor antagonist, lowers intraocular pressure in NZW rabbits","volume":"23","author":"Chidlow","year":"2001","journal-title":"Curr. Eye Res."},{"issue":"12","key":"10.1016\/j.ejps.2019.105173_bib0003","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1517\/17425255.2010.531259","article-title":"Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion","volume":"6","author":"Citrome","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.ejps.2019.105173_bib0004","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1006\/phrs.2001.0857","article-title":"Alpha-adrenoceptor subtypes","volume":"44","author":"Civantos Calzada","year":"2001","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.ejps.2019.105173_bib0005","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1527-3458.1997.tb00320.x","article-title":"Iloperidone: preclinical profile and early clinical evaluation","volume":"3","author":"Corbett","year":"1997","journal-title":"CNS Drug Rev."},{"issue":"2","key":"10.1016\/j.ejps.2019.105173_bib0006","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1517\/14740338.2014.854770","article-title":"Safety profile of iloperidone in the treatment of schizophrenia","volume":"13","author":"Dargani","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ejps.2019.105173_bib0007","article-title":"Anticancer activity of saponin isolated from Albizia lebbeck using various in vitro models","author":"Desai","year":"2018","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejps.2019.105173_bib0008","unstructured":"FDA. 22 Case studies where phase 2 and phase 3 trials had divergent results. 2017."},{"key":"10.1016\/j.ejps.2019.105173_bib0009","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemp. Clin. Trials Commun."},{"key":"10.1016\/j.ejps.2019.105173_bib0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2261-8-40","article-title":"Association of alpha1a-adrenergic receptor polymorphism and blood pressure phenotypes in the Brazilian population","volume":"8","author":"Freitas","year":"2008","journal-title":"BMC Cardiovasc. Disord."},{"issue":"3\u20134","key":"10.1016\/j.ejps.2019.105173_bib0011","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00213-003-1459-1","article-title":"Differential effects of iloperidone, clozapine, and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm","volume":"169","author":"Gemperle","year":"2003","journal-title":"Psychopharmacology"},{"issue":"Web Server issue","key":"10.1016\/j.ejps.2019.105173_bib0012","doi-asserted-by":"crossref","first-page":"W32","DOI":"10.1093\/nar\/gku293","article-title":"SwissTargetPrediction: a web server for target prediction of bioactive small molecules","volume":"42","author":"Gfeller","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"23","key":"10.1016\/j.ejps.2019.105173_bib0013","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1093\/bioinformatics\/btt540","article-title":"Shaping the interaction landscape of bioactive molecules","volume":"29","author":"Gfeller","year":"2013","journal-title":"Bioinformatics"},{"issue":"1\u20132","key":"10.1016\/j.ejps.2019.105173_bib0014","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3409\/fb61_1-2.79","article-title":"Comparison of the effect of alpha1- and alpha2-adrenoceptor agonists and antagonists on muscle contractility of the rabbit abdominal aorta in vitro","volume":"61","author":"Gnus","year":"2013","journal-title":"Folia Biol."},{"issue":"12","key":"10.1016\/j.ejps.2019.105173_bib0015","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1001\/jamainternmed.2016.6008","article-title":"Failure of investigational drugs in late-stage clinical development and publication of trial results","volume":"176","author":"Hwang","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ejps.2019.105173_bib0016","doi-asserted-by":"crossref","first-page":"e22039","DOI":"10.1002\/syn.22039","article-title":"Long-term effects of iloperidone on cerebral dopamine receptor subtypes","author":"Kee Choi","year":"2018","journal-title":"Synapse"},{"key":"10.1016\/j.ejps.2019.105173_bib0017","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/273060","article-title":"Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia","volume":"2014","author":"Khasawneh","year":"2014","journal-title":"Cardiol. Res. Pract."},{"issue":"9","key":"10.1016\/j.ejps.2019.105173_bib0018","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/archopht.1980.01020040491021","article-title":"Effect of prazosin on aqueous humor dynamics in rabbits","volume":"98","author":"Krupin","year":"1980","journal-title":"Arch. Ophthalmol."},{"issue":"2\u20133","key":"10.1016\/j.ejps.2019.105173_bib0019","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/minf.201000151","article-title":"QSAR modelling of rat acute toxicity on the basis of pass prediction","volume":"30","author":"Lagunin","year":"2011","journal-title":"Mol. Inf."},{"key":"10.1016\/j.ejps.2019.105173_bib0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-4939-7366-8_4","article-title":"YASARA: a tool to obtain structural guidance in biocatalytic investigations","volume":"1685","author":"Land","year":"2018","journal-title":"Methods Mol. Biol."},{"issue":"8","key":"10.1016\/j.ejps.2019.105173_bib0021","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","article-title":"Drug repositioning and repurposing: terminology and definitions in literature","volume":"20","author":"Langedijk","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.ejps.2019.105173_bib0022","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1021\/ci200227u","article-title":"LigPlot+: multiple ligand-protein interaction diagrams for drug discovery","volume":"51","author":"Laskowski","year":"2011","journal-title":"J. Chem. Inf. Model."},{"issue":"4","key":"10.1016\/j.ejps.2019.105173_bib0023","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1474-8673.2005.00348.x","article-title":"Chloroethylclonidine reveals that alpha (1 A)-adrenoceptors mediate contraction in aorta of alpha (1 D)-adrenoceptor knockout mice","volume":"25","author":"Lazaro-Suarez","year":"2005","journal-title":"Auton. Autacoid Pharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2019.105173_bib0024","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2019.105173_bib0025","first-page":"34","article-title":"Quetiapine-induced bradycardia and hypotension in the elderly-a case report","volume":"13","author":"Nakamura","year":"2016","journal-title":"Innov. Clin. Neurosci."},{"issue":"5","key":"10.1016\/j.ejps.2019.105173_bib0026","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.tips.2013.03.004","article-title":"Challenges and opportunities of drug repositioning","volume":"34","author":"Novac","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejps.2019.105173_bib0027","unstructured":"Package F.D.A. Fanapt (Iloperidone) Tablets. 12 June 2009."},{"issue":"1","key":"10.1016\/j.ejps.2019.105173_bib0028","first-page":"173","article-title":"Cross evaluation of different classes of alpha-adrenergic receptor antagonists to identify overlapping pharmacophoric requirements","volume":"6","author":"Pandey","year":"2013","journal-title":"J. Pharm. Res."},{"issue":"6","key":"10.1016\/j.ejps.2019.105173_bib0029","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1021\/ci000383k","article-title":"Robustness of biological activity spectra predicting by computer program PASS for noncongeneric sets of chemical compounds","volume":"40","author":"Poroikov","year":"2000","journal-title":"J. Chem. Inf. Comput. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2019.105173_bib0030","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1021\/ci020048r","article-title":"PASS biological activity spectrum predictions in the enhanced open NCI database browser","volume":"43","author":"Poroikov","year":"2003","journal-title":"J. Chem. Inf. Comput. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2019.105173_bib0031","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci."},{"issue":"9","key":"10.1016\/j.ejps.2019.105173_bib0032","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40263-017-0461-9","article-title":"Cardiovascular disease in clozapine-treated patients: evidence, mechanisms and management","volume":"31","author":"Ronaldson","year":"2017","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.ejps.2019.105173_bib0033","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1017\/S1092852913000850","article-title":"Role of \u03b11 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms","volume":"18","author":"Stahl","year":"2013","journal-title":"CNS Spectr."},{"issue":"3","key":"10.1016\/j.ejps.2019.105173_bib0034","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0278-5846(01)00307-4","article-title":"Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone","volume":"26","author":"Subramanian","year":"2002","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.ejps.2019.105173_bib0035","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0022-3565(25)20683-8","article-title":"Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2\/5-hydroxytryptamine2 receptor antagonist activity","volume":"278","author":"Szczepanik","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2019.105173_bib0036","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/CE.S114094","article-title":"Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy","volume":"11","author":"Tonin","year":"2016","journal-title":"Core Evid."},{"issue":"2","key":"10.1016\/j.ejps.2019.105173_bib0037","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"2","key":"10.1016\/j.ejps.2019.105173_bib0038","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.sbi.2009.02.008","article-title":"Convergence and combination of methods in protein-protein docking","volume":"19","author":"Vajda","year":"2009","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"W1","key":"10.1016\/j.ejps.2019.105173_bib0039","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: homology modelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.ejps.2019.105173_bib0040","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jemermed.2017.06.026","article-title":"Risperidone in the emergency setting is associated with more hypotension in elderly patients","volume":"53","author":"Wilson","year":"2017","journal-title":"J. Emerg. Med."},{"issue":"10","key":"10.1016\/j.ejps.2019.105173_bib0041","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int. J. Biol. Sci."},{"issue":"15","key":"10.1016\/j.ejps.2019.105173_bib0042","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/bioinformatics\/btr331","article-title":"Identification of cavities on protein surface using multiple computational approaches for drug binding site prediction","volume":"27","author":"Zhang","year":"2011","journal-title":"Bioinformatics"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719304464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719304464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:50:35Z","timestamp":1760529035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098719304464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":42,"alternative-id":["S0928098719304464"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105173","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing of Iloperidone: Antihypertensive and ocular hypotensive activity in animals","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105173"}}